Purple Biotech Ltd. (PPBT) is an Israeli clinical-stage immuno-oncology company whose American Depositary Receipts (ADRs) trade on the Nasdaq Capital Market. Because only one sell-side firm currently publishes a target, the stock does not support a meaningful aggregate analyst price target, so this article relies on a fallback target grounded in technical analysis and public discussion.
The lone current analyst view is from H.C. Wainwright's Emily Bodnar, who maintains a Buy rating. In August 2026, Wainwright lowered its target to $17 from $30, citing a low cash position and a significant increase in operating expenses. The $17 figure is a single analyst's discounted cash flow (DCF) estimate — implying roughly 1,200% upside — and should not be treated as an "analyst consensus." Because fewer than two credible, current targets exist, it cannot serve as the central target here.
The stock recently traded around $1.28, near the low end of a 52-week range of roughly $0.91 to $8.90. Reaching $2.00 would require a gain of about 56%, which is a substantial move. Purple Biotech has been deeply de-rated in 2026, weighed down by heavy dilution, a shrinking cash balance, and a transition in leadership. The path toward $2.00 would most plausibly run through a stabilization of the balance sheet, positive reception of preclinical CAPTN-3 data, and a broader recovery in risk appetite for micro-cap biotech names.
The clearest positive catalyst is the CAPTN-3 platform of masked tri-specific antibodies, which engages both T cells and NK (natural killer) cells within the tumor microenvironment. Lead candidate IM1240 was selected for an oral presentation at the 38th EORTC-NCI-AACR Symposium in November 2026, an event that has previously drawn investor attention to the program. A first-in-human study for IM1240 is planned for 2027, providing a tangible clinical milestone ahead. Separately, the company has reported about $6.1 million in cash, which it expects to fund operations into mid-2027, and a CEO transition has brought in Isaac Israel as interim chief executive. Regaining Nasdaq compliance and a successful near-term financing that limits dilution would both support sentiment.
Purple Biotech remains a deeply unprofitable, pre-revenue micro-cap with roughly $10.5 million in market capitalization and a large share count following at-the-market (ATM) sales. Continued equity issuance could keep downward pressure on the share price and make a 56% recovery difficult to sustain. The company has also flagged the risk of Nasdaq delisting if its ADSs fail minimum bid price requirements, which could erode institutional interest and liquidity. Preclinical results may not translate into clinical success, and the next year offers no human efficacy data, leaving a long gap between catalysts. Execution risk around management transition and general weakness in small-cap biotechnology are additional headwinds.
The stock's technical backdrop is challenging. The $0.91 52-week low is the key support level to monitor, while the $1.00 psychological level carries added significance because it approximates Nasdaq's minimum bid price threshold. On the upside, $2.00 represents a round-number recovery milestone, but the shares would first need to clear the $1.50 area before any sustained move toward the target. The $8.90 52-week high remains a distant resistance level and underscores how far the stock has fallen.
Analyst price targets typically reflect a roughly 12-month research horizon, though with only one covering firm, the practical signal here is limited. Investors should monitor the IM1240 oral presentation and any preclinical data updates for IM1240 and IM1305, the company's third-quarter results (estimated for mid-November 2026, with a consensus loss of about $2.88 per share), cash runway commentary, any new financing or ATM activity, Nasdaq compliance status, and leadership updates. No definitive forecast is implied by the $2.00 level.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, including volatile micro-cap names like PPBT, and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use the tool to surface opportunities, keep an eye on existing positions, and spot shifting trends more efficiently than manual screening allows. For those following the evolving story in clinical-stage biotech, this kind of signal can help put daily price action into a broader, data-driven context.
The $2.00 central target is a fallback, technical-recovery milestone rather than an analyst consensus, since only one firm publishes a target for PPBT. With shares near $1.28, reaching that level would require a substantial gain of roughly 56%. The bull case rests on the CAPTN-3 platform, the IM1240 oral presentation, and a planned 2027 first-in-human study, while the bear case centers on a low cash balance, ongoing dilution, Nasdaq compliance risk, and a long wait for clinical data. Investors should focus next on the symposium presentation, quarterly results, financing activity, and cash runway updates, recognizing that the stock remains highly speculative and that no price outcome is guaranteed.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, PPBT has been loosely correlated with SNTI. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if PPBT jumps, then SNTI could also see price increases.
| Ticker / NAME | Correlation To PPBT | 1D Price Change % | ||
|---|---|---|---|---|
| PPBT | 100% | +11.94% | ||
| SNTI - PPBT | 57% Loosely correlated | +11.81% | ||
| ATOS - PPBT | 35% Loosely correlated | -5.14% | ||
| BCYC - PPBT | 32% Poorly correlated | N/A | ||
| APLM - PPBT | 31% Poorly correlated | -3.05% | ||
| CCCC - PPBT | 27% Poorly correlated | -3.67% | ||
More | ||||